Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors

Author:

Bartalena Luigi1,Gallo Daniela2,Tanda Maria Laura2,Kahaly George J.3

Affiliation:

1. School of Medicine

2. Department of Medicine and Surgery, University of Insubria, Varese, Italy

3. Department of Medicine I, Johannes Gutenberg University, Mainz, Germany

Abstract

Background: Thyroid eye disease (TED) is an autoimmune disorder of the orbit and the most frequent extrathyroidal manifestation of Graves’ disease but it may rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. Epidemiology: TED is a relatively infrequent disorder, particularly in its severe forms. Men tend to have more severe TED at an older age. The prevalence of TED is lower than in the past among patients with recent onset Graves’ hyperthyroidism, and moderate-to-severe forms requiring aggressive treatments are no more than 5% to 6% of all cases. Natural history: After an initial inflammatory (active) phase and a plateau phase, TED stabilizes and eventually inactivates (inactive or burnt-out phase) after an estimated period of 18–24 months. Minimal-to-mild TED often remits spontaneously, but complete restitutio ad integrum almost never occurs when TED is more than mild. Risk factors: Several risk factors contribute to its development on a yet undefined genetic background. Cigarette smoking is the most important of them, but thyroid dysfunction (both hyper- and hypothyroidism), radioactive iodine therapy (if not accompanied by low-dose steroid prophylaxis), elevated thyrotropin receptor antibodies, and, probably, hypercholesterolemia represent relevant modifiable risk factors. Early diagnosis, control and removal of modifiable risk factors, and early treatment of mild forms of GO (local treatment and selenium) may effectively limit the risk of progression to more severe forms.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine,Surgery

Reference75 articles.

1. Current concepts regarding Graves’ orbitopathy.;Bartalena;J Intern Med,2022

2. New insights into the pathogenesis and nonsurgical management of Graves’ orbitopathy.;Taylor;Nat Rev Endocrinol,2020

3. Thyrotropin receptor antibodies and Graves’ orbitopathy.;Diana;J Endocrinol Invest,2021

4. 2021 update on thyroid-associated ophthalmopathy.;Neag;J Endocrinol Invest,2022

5. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.;Bartley;Trans Am Ophthalmol Soc,1994

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3